

Resource Summary Report

Generated by [dkNET](#) on Aug 31, 2026

Phospho-p90RSK (Thr359/Ser363) Antibody

RRID:AB_331650

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9344, RRID:AB_331650

Antibody Information

URL: http://antibodyregistry.org/AB_331650

Proper Citation: Cell Signaling Technology Cat# 9344, RRID:AB_331650

Target Antigen: Phospho-p90RSK (Thr359/Ser363)

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP. Consolidation on 11/2018: AB_10078330, AB_10827915, AB_331650.

Antibody Name: Phospho-p90RSK (Thr359/Ser363) Antibody

Description: This polyclonal targets Phospho-p90RSK (Thr359/Ser363)

Target Organism: rat, h, m, mouse, r, human, mk

Antibody ID: AB_331650

Vendor: Cell Signaling Technology

Catalog Number: 9344

Record Creation Time: 20250819T220315+0000

Record Last Update: 20250820T005715+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-p90RSK (Thr359/Ser363) Antibody.

No alerts have been found for Phospho-p90RSK (Thr359/Ser363) Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#).

Lan T, et al. (2026) RSK1-SRF signaling axis drives fibroblast activation and pulmonary fibrosis: Genetic causality and therapeutic targeting. *iScience*, 29(5), 115495.

Chatterjee D, et al. (2025) KSR1 Mediates Small Cell Lung Carcinoma Tumor Initiation and Cisplatin Resistance. *Molecular cancer research : MCR*, 23(6), 553.

Constantin D, et al. (2024) MR1 Gene and Protein Expression Are Enhanced by Inhibition of the Extracellular Signal-Regulated Kinase ERK. *Cancer immunology research*, 12(10), 1452.

Klomp JE, et al. (2024) Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer. *Science (New York, N.Y.)*, 384(6700), eadk0850.

Klomp JA, et al. (2024) Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers. *Science (New York, N.Y.)*, 384(6700), eadk0775.

Vallés-Martí A, et al. (2023) Phosphoproteomics guides effective low-dose drug combinations against pancreatic ductal adenocarcinoma. *Cell reports*, 42(6), 112581.

Frank KJ, et al. (2022) Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer. *Cell reports. Medicine*, 3(11), 100815.

Whiteaker JR, et al. (2021) Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling. *Cell reports methods*, 1(3).

Waters AM, et al. (2021) Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. *Cell reports*, 35(13), 109291.

Ozkan-Dagliyan I, et al. (2020) Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. *Cell reports*, 31(11), 107764.

Stein BD, et al. (2019) Quantitative In Vivo Proteomics of Metformin Response in Liver Reveals AMPK-Dependent and -Independent Signaling Networks. *Cell reports*, 29(10), 3331.

Vaseva AV, et al. (2018) KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. *Cancer cell*, 34(5), 807.

Hill SM, et al. (2017) Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling. *Cell systems*, 4(1), 73.